Masitinib is developed in several human indications, in oncology, inflammatory diseases, and central nervous system diseases. Masitinib has been evaluated in around 4000 human patients to date.
Masitinib also generated positive phase 2 results in oncology, inflammatory diseases, as well as CNS diseases. Several phases 3 are on-going in those indications.
|Oncology / Hematology||GIST in first-line treatment||Phase 3||On-going|
|GIST in second-line treatment||Phase 3||On-going|
|Metastatic melanoma with JM mutation of c-KIT||Phase 3||On-going|
|Pancreatic cancer||Phase 3||On-going|
|Relapsed metastatic colorectal cancer||Phase 3||On-going|
|Castrate Resistant Prostate Cancer in first line||Phase 3||On-going|
|Relapsed metastatic ovarian cancer||Phase 3||On-going|
|Relapsed peripheral T-cell lymphoma||Phase 3||On-going|
|Inflammatory and neuro-degenerative diseases||Severe asthma uncontrolled by oral corticosteroids||Phase 3||Recruitment completed|
|Severe asthma uncontrolled by oral corticosteroids and with elevated eosinophil level||Phase 3||On-going|
|Alzheimer disease||Phase 3||On-going|
|Progressive forms of multiple sclerosis||Phase 3||On-going|
|Amyotrophic lateral sclerosis||Phase 3||Study completed|